drugset / Trial / NCT05257395
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase III clinical trial designed to evaluate the efficacy and safety of XZP-3287 in combination with Letrozole/Anastrozole versus placebo in combination with Letrozole/Anastrozole in patients with HR-positive and HER2-negative recurrent/metastatic breast cancer who have not received systemic anticancer therapy.
Timeline
- Start
- 2022-03-14
- Primary completion
- 2025-12-05
- Completion
- 2030-09-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XZP-3287 | Unknown | 360 mg | Oral |
| Background | Anastrozole | Other / unclassified | 1 mg | Oral |
| Background | Letrozole | Other / unclassified | 2.5 mg | Oral |